CompletedNot Applicable

Probiotics in Intestinal Bacterial Overgrowth

Greece26 participantsStarted 2014-09

Plain-language summary

The aim of the present study is to demonstrate the effect of a mixture of four species of probiotics (Saccharomyces boulardii, Bifidobacterium lactis BB-12, Lactobacillus acidophilus LA-5 and Lactobacillus plantarum) in patients with symptomatic irritable bowel syndrome (IBS) who have culture verified syndrome of intestinal bacterial overgrowth (SIBO) and those who do not have. This will provide direct evidence for the role of probiotics in treating part of the pathogenesis of IBS.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age ≥18 years
✓. Both genders
✓. Written informed consent by study participants
✓. Presence of IBS according to Rome III criteria
✓. Equal number of SIBO-positive and SIBO-negative patients

Exclusion criteria

✕. Age \<18 years
✕. Deny to consent
✕. Pregnancy or lactation
✕. Presence of inflammatory bowel disease
✕. Presence of acute GI tract infection
✕. Diabetes mellitus type 1 or type 2
✕. Use of laxatives and antibiotics within the preceding 6 weeks
✕. Presence of fever, abdominal mass, signs of bowel obstruction and/or leucocytosis

What they're measuring

• The efficacy of probiotics in improvement of symptoms of IBS in patients with SIBO compared to their efficacy in patients with IBS without SIBO.

Timeframe: 30 days

Trial details

NCT IDNCT02204891

SponsorUniversity of Athens

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2016-06

View on ClinicalTrials.gov More Irritable Bowel Syndrome trials